Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 283

1.

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.

Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, Herrero R, Hildesheim A; Costa Rican Vaccine Trial Group..

J Natl Cancer Inst. 2010 Nov 3;102(21):1653-62. doi: 10.1093/jnci/djq384.

2.

Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.

Coseo S, Porras C, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Gonzalez P, Wang SS, Sherman ME, Jimenez S, Solomon D, Bougelet C, van Doorn LJ, Quint W, Safaeian M; Costa Rica HPV Vaccine Trial (CVT) Group..

Sex Transm Dis. 2010 Nov;37(11):706-14. doi: 10.1097/OLQ.0b013e3181e1a2c5.

PMID:
20661178
3.

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

Beachler DC, Kreimer AR, Schiffman M, Herrero R, Wacholder S, Rodriguez AC, Lowy DR, Porras C, Schiller JT, Quint W, Jimenez S, Safaeian M, Struijk L, Schussler J, Hildesheim A, Gonzalez P; Costa Rica HPV Vaccine Trial (CVT) Group..

J Natl Cancer Inst. 2015 Oct 14;108(1). pii: djv302. doi: 10.1093/jnci/djv302.

PMID:
26467666
4.

Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.

Coseo SE, Porras C, Dodd LE, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Gonzalez P, Sherman ME, Jimenez S, Solomon D, Bougelet C, van Doorn LJ, Quint W, Safaeian M; Costa Rica HPV Vaccine Trial (CVT) Group..

Sex Transm Dis. 2011 Oct;38(10):976-82. doi: 10.1097/OLQ.0b013e31822545c0.

5.

Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.

Robbins HA, Li Y, Porras C, Pawlita M, Ghosh A, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Gonzalez P, Schiller J, Lowy D, Esser M, Matys K, Quint W, van Doorn LJ, Herrero R, Pinto LA, Hildesheim A, Waterboer T, Safaeian M.

BMC Infect Dis. 2014 Mar 3;14:120. doi: 10.1186/1471-2334-14-120.

6.

Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.

Robbins HA, Waterboer T, Porras C, Kemp TJ, Pawlita M, Rodriguez AC, Wacholder S, Gonzalez P, Schiller JT, Lowy DR, Esser M, Matys K, Poncelet S, Herrero R, Hildesheim A, Pinto LA, Safaeian M.

Hum Vaccin Immunother. 2014;10(10):2965-74. doi: 10.4161/21645515.2014.972811.

PMID:
25483632
7.

[Distribution of serum antibodies against human papillomavirus 16 and 18 among high-risk women to cervical cancer].

Fei M, Li J, Du J, You J, Zhang S, He W, Kang L, Zhao F, Qiao Y, Si Y, Fan X, Chen W.

Zhonghua Liu Xing Bing Xue Za Zhi. 2014 May;35(5):514-8. Chinese.

PMID:
25059358
8.

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.

Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.

Hum Vaccin Immunother. 2013 Jul;9(7):1399-406. doi: 10.4161/hv.24340.

9.

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.

Kreimer AR, González P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jiménez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R; CVT Vaccine Group..

Lancet Oncol. 2011 Sep;12(9):862-70. doi: 10.1016/S1470-2045(11)70213-3. Erratum in: Lancet Oncol. 2011 Nov;12(12):1096.

10.

Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

Castellsagué X, Naud P, Chow SN, Wheeler CM, Germar MJ, Lehtinen M, Paavonen J, Jaisamrarn U, Garland SM, Salmerón J, Apter D, Kitchener H, Teixeira JC, Skinner SR, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Peters K, Tjalma WA, Safaeian M, Raillard A, Descamps D, Struyf F, Dubin G, Rosillon D, Baril L.

J Infect Dis. 2014 Aug 15;210(4):517-34. doi: 10.1093/infdis/jiu139.

11.

Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.

Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, Chen S, Quint W, Lowy DR, Porras C, DelVecchio C, Jimenez S, Safaeian M, Schiller JT, Wacholder S, Herrero R, Hildesheim A, Kreimer AR; Costa Rica Vaccine Trial Group..

J Infect Dis. 2014 Dec 15;210(12):1890-9. doi: 10.1093/infdis/jiu357.

12.

Determinants of seropositivity among HPV-16/18 DNA positive young women.

Porras C, Bennett C, Safaeian M, Coseo S, Rodríguez AC, González P, Hutchinson M, Jiménez S, Sherman ME, Wacholder S, Solomon D, van Doorn LJ, Bougelet C, Quint W, Schiffman M, Herrero R, Hildesheim A; Costa Rica HPV Vaccine Trial (CVT) Group..

BMC Infect Dis. 2010 Aug 11;10:238. doi: 10.1186/1471-2334-10-238.

13.
14.

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA; CVT Group..

Cancer Prev Res (Phila). 2013 Nov;6(11):1242-50. doi: 10.1158/1940-6207.CAPR-13-0203. Erratum in: Cancer Prev Res (Phila). 2016 Jan;9(1):116-7.

15.

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.

Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S; CVT Vaccine Group..

J Natl Cancer Inst. 2011 Oct 5;103(19):1444-51. doi: 10.1093/jnci/djr319.

16.

Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot study.

Namujju PB, Pajunen E, Simen-Kapeu A, Hedman L, Merikukka M, Surcel HM, Kirnbauer R, Apter D, Paavonen J, Hedman K, Lehtinen M.

BMC Res Notes. 2014 Jul 11;7:445. doi: 10.1186/1756-0500-7-445.

17.

Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.

Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA, Lehtinen MO, Steben M, Joura EA, Giacoletti KE, Radley DR, James MK, Saah AJ, Sings HL; FUTURE I and II Investigators..

Int J Cancer. 2011 Dec 1;129(11):2632-42. doi: 10.1002/ijc.25940.

18.

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G; HPV PATRICIA study group..

Lancet. 2007 Jun 30;369(9580):2161-70. Erratum in: Lancet. 2007 Oct 20;370(9596):1414.

PMID:
17602732
19.

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women.

Sow PS, Watson-Jones D, Kiviat N, Changalucha J, Mbaye KD, Brown J, Bousso K, Kavishe B, Andreasen A, Toure M, Kapiga S, Mayaud P, Hayes R, Lebacq M, Herazeh M, Thomas F, Descamps D.

J Infect Dis. 2013 Jun 1;207(11):1753-63. doi: 10.1093/infdis/jis619.

20.

Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.

Heijstek MW, Scherpenisse M, Groot N, Tacke C, Schepp RM, Buisman AM, Berbers GA, van der Klis FR, Wulffraat NM.

Ann Rheum Dis. 2014 Aug;73(8):1500-7. doi: 10.1136/annrheumdis-2013-203429.

PMID:
23723319
Items per page

Supplemental Content

Support Center